LLY ▼ -0.2% - Eli Lilly and Company
$LLY - Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
29-SEP-2026 06:00 PM ET
Share this post
More filings for $LLY
LLY ▲ +0.0% - Eli Lilly and CompanySep 29, 2026LLY ▼ -0.8% - Eli Lilly and CompanySep 29, 2026LLY ▼ -0.1% - Eli Lilly and CompanySep 29, 2026LLY ▲ +0.2% - Eli Lilly and CompanySep 29, 2026LLY ▲ +0.3% - Eli Lilly and CompanySep 29, 2026LLY ▲ +0.6% - Eli Lilly and CompanySep 28, 2026
View full $LLY filing history →💬 Comments
Loading comments…
Leave a comment